ROTE WILLIAM E.
SEC CIK 1698262 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | SVP, R, D | 211.0K | — | $17.30M | 36 | 2021-08-13 | 2026-09-15 |
Most active insiders at TVTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Dube Eric M | CEO, Dir | — | $41.35M |
| 2 | Heerma Peter | EVP, Chief COMMERCIAL Off | — | $18.97M |
| 3 | ROTE WILLIAM E. | Chief Research Off | — | $16.43M |
| 4 | REED ELIZABETH E | CLO, GC | — | $7.02M |
| 5 | Inrig Jula | EVP, CMO, Head of R, D | — | $5.16M |
| 6 | Cline Christopher R. | CFO | — | $4.64M |
| 7 | Calvin Sandra | SVP, CAO | — | $4.19M |
| 8 | Baynes Roy D. | Dir | — | $2.55M |
| 9 | Meckler Jeffrey A | Dir | — | $1.71M |
| 10 | Coughlin Timothy | Dir | — | $1.27M |
Transactions 36
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-17 21:35 | 2026-09-15+ | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | M - OptEx | $21.40 | +191.5K | 211.0K | +980% | +$4.10M |
| DMT | 2026-09-17 21:35 | 2026-09-15+ | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | S - Sale+OE | $62.83 | -209.0K | 98.2K | -68% | -$13.14M |
| DT | 2026-05-06 20:00 | 2026-05-04 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | M - OptEx | $0.00 | +4,250 | 118.2K | +4% | $0 |
| DT | 2026-05-06 20:00 | 2026-05-06 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | S - Sale+OE | $43.95 | -2,763 | 115.5K | -2% | -$121.4K |
| T | 2026-04-23 16:05 | 2026-04-22 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | S - Sale | $39.09 | -9,100 | 114.0K | -7% | -$355.7K |
| T | 2026-04-15 21:48 | 2026-04-13 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | A - Grant | $0.00 | +14.0K | 123.1K | +13% | $0 |
| D | 2026-02-03 | 2026-01-31 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | A - Grant | $0.00 | +20.1K | 121.5K | +20% | $0 |
| D | 2026-02-03 | 2026-02-03 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | S - Sale | $32.87 | -12.4K | 109.1K | -10% | -$409.1K |
| D | 2025-12-29 | 2025-12-24 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | S - Sale+OE | $40.10 | -60.0K | 101.4K | -37% | -$2.41M |
| D | 2025-12-29 | 2025-12-24 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | M - OptEx | $20.61 | +60.0K | 161.4K | +59% | +$1.24M |
| D | 2025-05-05 | 2025-05-02 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | M - OptEx | — | +4,920 | 103.4K | +5% | — |
| D | 2025-05-05 | 2025-05-05 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | Chief Research Off | S - Sale+OE | $21.05 | -3,198 | 100.2K | -3% | -$67.3K |
| D | 2025-02-12 | 2025-02-12 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale+OE | $23.53 | -5,200 | 98.5K | -5% | -$122.4K |
| D | 2025-02-12 | 2025-02-10 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | M - OptEx | — | +8,000 | 103.7K | +8% | — |
| D | 2025-02-04 | 2025-02-03 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $19.78 | -8,951 | 95.7K | -9% | -$177.1K |
| D | 2025-02-04 | 2025-01-31 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | A - Grant | $0.00 | +21.5K | 104.7K | +26% | $0 |
| 2025-01-23 | 2025-01-22 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $19.46 | -2,437 | 83.2K | -3% | -$47.4K | |
| 2024-09-09 | 2024-09-09 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $11.52 | -4,387 | 84.5K | -5% | -$50.5K | |
| 2024-09-09 | 2024-09-05 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | A - Grant | $0.00 | +6,750 | 88.8K | +8% | $0 | |
| D | 2024-02-02 | 2024-01-31 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | A - Grant | $0.00 | +25.0K | 85.5K | +41% | $0 |
| DM | 2024-02-02 | 2024-02-01 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $8.71 | -4,764 | 83.3K | -5% | -$41.5K |
| 2024-01-25 | 2024-01-23 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $8.96 | -2,062 | 60.5K | -3% | -$18.5K | |
| 2023-09-05 | 2023-08-31 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | A - Grant | $0.00 | +3,300 | 63.0K | +6% | $0 | |
| 2023-09-05 | 2023-09-05 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $14.71 | -1,815 | 61.2K | -3% | -$26.7K | |
| 2023-05-12 | 2023-05-10 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $16.59 | -825 | 59.2K | -1% | -$13.7K | |
| D | 2023-02-02 | 2023-02-01 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $22.25 | -2,590 | 60.0K | -4% | -$57.6K |
| D | 2023-02-02 | 2023-01-31 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | A - Grant | $0.00 | +20.2K | 62.6K | +48% | $0 |
| 2023-01-26 | 2023-01-24 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $21.50 | -2,062 | 42.4K | -5% | -$44.3K | |
| M | 2022-05-12 | 2022-05-11 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $21.72 | -1,563 | 43.7K | -3% | -$33.9K |
| D | 2022-02-02 | 2022-01-31 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | A - Grant | $0.00 | +9,840 | 46.4K | +27% | $0 |
| D | 2022-02-02 | 2022-01-31 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $27.40 | -1,125 | 45.2K | -2% | -$30.8K |
| 2022-01-26 | 2022-01-24 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $24.98 | -1,875 | 36.5K | -5% | -$46.8K | |
| 2022-01-12 | 2022-01-11 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $27.40 | -2,500 | 38.4K | -6% | -$68.5K | |
| 2022-01-12 | 2022-01-10 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | A - Grant | $0.00 | +5,000 | 40.9K | +14% | $0 | |
| 2021-08-17 | 2021-08-13 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | A - Grant | $0.00 | +4,500 | 37.1K | +14% | $0 | |
| 2021-08-17 | 2021-08-17 | TVTX | Travere Therapeutics, Inc. | ROTE WILLIAM E. | SVP, R, D | S - Sale | $17.12 | -1,407 | 35.7K | -4% | -$24.1K |
Purchase Sale Sale after option exercise All abbreviations